NephroGuard

Prevent Acute Kidney Injury (AKI) in patients undergoing major surgical procedures such as heart surgery and organ transplant (e.g liver and kidney transplant).

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Los Angeles, CA, USA
  • Currency USD
  • Founded April 2013
  • Employees 3
  • Website nephroguard.com

Company Summary

Acute Kidney Injury (AKI) is a sudden decrease in kidney function that affects 5% of all hospitalized patients (~ 1.2 million in the US) each year. With no treatment options available, AKI is associated with high morbidity and mortality; and imposes a huge financial burden on health care system.

NephroGuard has developed a compound that can effectively prevent AKI in patients and is proved to be safe in humans through phase 1 clinical trials.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free